vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and ASPEN AEROGELS INC (ASPN). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $41.3M, roughly 1.1× ASPEN AEROGELS INC). Amarin Corp plc runs the higher net margin — -23.3% vs -176.4%, a 153.1% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -66.4%). Over the past eight quarters, Amarin Corp plc's revenue compounded faster (-18.3% CAGR vs -33.9%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Aspen Aerogels Inc is a leading manufacturer of high-performance aerogel-based insulation and thermal management materials. It serves core sectors including renewable energy, oil and gas infrastructure, aerospace, commercial construction and industrial manufacturing, with key markets across North America, Europe and Asia-Pacific. Its products are prized for superior thermal resistance, fire safety and lightweight performance for harsh operating conditions.

AMRN vs ASPN — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.1× larger
AMRN
$45.1M
$41.3M
ASPN
Growing faster (revenue YoY)
AMRN
AMRN
+73.4% gap
AMRN
7.0%
-66.4%
ASPN
Higher net margin
AMRN
AMRN
153.1% more per $
AMRN
-23.3%
-176.4%
ASPN
Faster 2-yr revenue CAGR
AMRN
AMRN
Annualised
AMRN
-18.3%
-33.9%
ASPN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
ASPN
ASPN
Revenue
$45.1M
$41.3M
Net Profit
$-10.5M
$-72.9M
Gross Margin
-55.5%
Operating Margin
35.5%
-170.3%
Net Margin
-23.3%
-176.4%
Revenue YoY
7.0%
-66.4%
Net Profit YoY
33.0%
-741.7%
EPS (diluted)
$-0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
ASPN
ASPN
Q1 26
$45.1M
Q4 25
$49.2M
$41.3M
Q3 25
$49.7M
$73.0M
Q2 25
$72.7M
$78.0M
Q1 25
$42.0M
$78.7M
Q4 24
$62.3M
$123.1M
Q3 24
$42.3M
$117.3M
Q2 24
$67.5M
$117.8M
Net Profit
AMRN
AMRN
ASPN
ASPN
Q1 26
$-10.5M
Q4 25
$-1.2M
$-72.9M
Q3 25
$-7.7M
$-6.3M
Q2 25
$-14.1M
$-9.1M
Q1 25
$-15.7M
$-301.2M
Q4 24
$-48.6M
$11.4M
Q3 24
$-25.1M
$-13.0M
Q2 24
$1.5M
$16.8M
Gross Margin
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
47.1%
-55.5%
Q3 25
44.7%
28.5%
Q2 25
69.2%
32.4%
Q1 25
59.8%
29.0%
Q4 24
-15.4%
38.3%
Q3 24
38.5%
41.8%
Q2 24
63.4%
43.8%
Operating Margin
AMRN
AMRN
ASPN
ASPN
Q1 26
35.5%
Q4 25
-12.9%
-170.3%
Q3 25
-22.4%
-4.6%
Q2 25
-22.0%
-6.6%
Q1 25
-39.9%
-380.2%
Q4 24
-84.3%
12.0%
Q3 24
-59.5%
14.8%
Q2 24
-0.8%
17.0%
Net Margin
AMRN
AMRN
ASPN
ASPN
Q1 26
-23.3%
Q4 25
-2.5%
-176.4%
Q3 25
-15.6%
-8.7%
Q2 25
-19.4%
-11.6%
Q1 25
-37.4%
-382.7%
Q4 24
-78.0%
9.2%
Q3 24
-59.4%
-11.1%
Q2 24
2.3%
14.3%
EPS (diluted)
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
$0.00
$-0.87
Q3 25
$-0.02
$-0.08
Q2 25
$-0.03
$-0.11
Q1 25
$-0.04
$-3.67
Q4 24
$-0.12
$0.15
Q3 24
$-0.06
$-0.17
Q2 24
$0.00
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
ASPN
ASPN
Cash + ST InvestmentsLiquidity on hand
$307.8M
$156.9M
Total DebtLower is stronger
$65.5M
Stockholders' EquityBook value
$235.5M
Total Assets
$645.8M
$406.7M
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
ASPN
ASPN
Q1 26
$307.8M
Q4 25
$302.6M
$156.9M
Q3 25
$286.6M
$150.7M
Q2 25
$298.7M
$167.6M
Q1 25
$281.8M
$192.0M
Q4 24
$294.2M
$220.9M
Q3 24
$305.7M
$113.5M
Q2 24
$306.7M
$91.4M
Total Debt
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
$65.5M
Q3 25
$70.1M
Q2 25
$77.3M
Q1 25
$95.4M
Q4 24
$95.0M
Q3 24
$93.7M
Q2 24
Stockholders' Equity
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
$459.3M
$235.5M
Q3 25
$458.9M
$305.7M
Q2 25
$464.9M
$308.8M
Q1 25
$473.7M
$314.8M
Q4 24
$486.2M
$614.7M
Q3 24
$531.4M
$507.6M
Q2 24
$551.9M
$517.8M
Total Assets
AMRN
AMRN
ASPN
ASPN
Q1 26
$645.8M
Q4 25
$670.8M
$406.7M
Q3 25
$659.8M
$491.4M
Q2 25
$670.1M
$525.1M
Q1 25
$655.7M
$555.0M
Q4 24
$685.3M
$895.1M
Q3 24
$750.6M
$782.6M
Q2 24
$799.9M
$748.6M
Debt / Equity
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
0.28×
Q3 25
0.23×
Q2 25
0.25×
Q1 25
0.30×
Q4 24
0.15×
Q3 24
0.18×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
ASPN
ASPN
Operating Cash FlowLast quarter
$16.1M
Free Cash FlowOCF − Capex
$13.7M
FCF MarginFCF / Revenue
33.1%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
$15.3M
$16.1M
Q3 25
$-12.7M
$15.0M
Q2 25
$16.6M
$-3.9M
Q1 25
$-12.5M
$5.6M
Q4 24
$-13.3M
$35.7M
Q3 24
$-2.4M
$20.8M
Q2 24
$-2.7M
$6.8M
Free Cash Flow
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
$13.7M
Q3 25
$5.9M
Q2 25
$-16.8M
Q1 25
$-7.4M
Q4 24
$20.9M
Q3 24
$-50.0K
Q2 24
$-18.0M
FCF Margin
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
33.1%
Q3 25
8.1%
Q2 25
-21.6%
Q1 25
-9.4%
Q4 24
17.0%
Q3 24
-0.0%
Q2 24
-15.3%
Capex Intensity
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
6.0%
Q3 25
12.5%
Q2 25
16.5%
Q1 25
16.5%
Q4 24
12.0%
Q3 24
17.7%
Q2 24
21.1%
Cash Conversion
AMRN
AMRN
ASPN
ASPN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
3.14×
Q3 24
Q2 24
-1.81×
0.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

ASPN
ASPN

Energy Industrial$14.5M35%
Other$13.9M34%
Thermal Barrier$12.9M31%

Related Comparisons